Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2009-06-16
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S362500
Reexamination Certificate
active
07547720
ABSTRACT:
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Meno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5348968 (1994-09-01), Lavielle et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5573758 (1996-11-01), Adorante et al.
patent: 5889052 (1999-03-01), Klinko et al.
patent: 5925342 (1999-07-01), Adorante et al.
patent: 6956036 (2005-10-01), May et al.
patent: 1 114816 (1999-09-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 94/28900 (1994-12-01), None
patent: WO 96/33719 (1996-10-01), None
patent: WO 89/10757 (1998-11-01), None
patent: WO 01 52876 (2000-01-01), None
patent: WO 01 70701 (2000-11-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/72268 (2001-10-01), None
patent: WO 02/24647 (2002-03-01), None
patent: WO 02/42268 (2002-05-01), None
patent: WO 03011833 (2003-02-01), None
Wiederholt et al. (Progress in Retinal & Eye Research 2000, 19(3), 271-295).
Harman et al., “Development and Aging of Cell Topography in the Human Retinal Pigment Epithelium”, 1997, pp. 2016-2026, vol. 38, Investigative Ophthalmology & Visual Science.
Berge et al., “Pharmaceutical Salts”, 1977, pp. 1-19, vol. 66, Journal of Pharmaceutical Sciences.
Hanner et al., “The β Subunit of High Conductance Calcium-Activated Potassium Channel”, 1998 pp. 16283-16296, vol. 273, J. Biol. Chem.
Vasallo et al., “Expression of Na,K-ATPase Alpha Subunit Isoforms in the Human Ciliary Body and Cultured Ciliary Epithelial Cells”, 1989, pp. 243-252, vol. 141, Journal of Cellular Physiology.
Ero et al., “New Antifungal 1,2,4-Triazoles with Difluoro (heteroaryl) methyl Moiety”, 2000, pp. 982-990, vol. 48, Chem. Pharm. Bull.
Y. Hirai et al., Japan Patent 89-207208 (Chemical Abstract, 1990 112, 32154a).
T. Morie et al., “Convenient Synthesis of N-(2,2-Dimethyl-1,3-Dioxan-5-YL)-1H-Indazole-3-Carboxamide, the Intermediate of 5-HT3 Receptor Antagonist”, 1997, pp. 559-566, vol. 27 (4), Synthetic Communications.
T. Yoshida et al., “Practical Synthesis of 1H-INdazole-3-Carboxylic Acid and its Derivatives”, 1996, pp. 2701-2712, vol. 27 (4), Heterocycles.
Beilstein Regisry No. 91608, XP-002275106. 1965.
Beilstein Registry No. 144953, XP-002275105, 1920.
Beilstein Registry No. 888594, XP-002275104, 1972.
Beilstein Registry No. 224495, XP-002275107, 1924.
Chen Meng-Hsin
Doherty James B.
Liu Luping
Natarajan Swaminathan R.
Tynebor Robert M.
Anderson Rebecca L
Ayler Sylvia A.
Krovatin William
Merck & Co. , Inc.
Nolan Jason
LandOfFree
Ophthalmic compositions for treating ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic compositions for treating ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions for treating ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106258